Literature DB >> 29228381

Etiology and Impact of Coinfections in Children Hospitalized With Community-Acquired Pneumonia.

Vikki G Nolan1, Sandra R Arnold2, Anna M Bramley3, Krow Ampofo4, Derek J Williams5, Carlos G Grijalva6, Wesley H Self7, Evan J Anderson8, Richard G Wunderink9, Kathryn M Edwards5, Andrew T Pavia4, Seema Jain3, Jonathan A McCullers2.   

Abstract

Background: Recognition that coinfections are common in children with community-acquired pneumonia (CAP) is increasing, but gaps remain in our understanding of their frequency and importance.
Methods: We analyzed data from 2219 children hospitalized with CAP and compared demographic and clinical characteristics and outcomes between groups with viruses alone, bacteria alone, or coinfections. We also assessed the frequency of selected pairings of codetected pathogens and their clinical characteristics.
Results: A total of 576 children (26%) had a coinfection. Children with only virus detected were younger, more likely to be black, and more likely to have comorbidities such as asthma, compared with children infected with typical bacteria alone. Children with virus-bacterium coinfections had a higher frequency of leukocytosis, consolidation on chest radiography, parapneumonic effusions, intensive care unit admission, and need for mechanical ventilation and an increased length of stay, compared with children infected with viruses alone. Virus-virus coinfections were generally comparable to single-virus infections, with the exception of the need for oxygen supplementation, which was higher during the first 24 hours of hospitalization in some virus-virus pairings. Conclusions: Coinfections occurred in 26% of children hospitalized for CAP. Children with typical bacterial infections, alone or complicated by a viral infection, have worse outcomes than children infected with a virus alone.

Entities:  

Mesh:

Year:  2018        PMID: 29228381      PMCID: PMC7108488          DOI: 10.1093/infdis/jix641

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


( Community-acquired pneumonia (CAP) is an important cause of morbidity and mortality in children [1]. The advent of molecular testing has markedly enhanced the detection of respiratory viruses and has demonstrated that virus-bacterium and virus-virus coinfections are common among children with CAP and contribute to pathogenesis [1-3]. For example, during the 2009 influenza A(H1N1) pandemic, a coinfecting bacterial pathogen was identified in about one third of all severe or fatal infections due to 2009 pandemic influenza A(H1N1) virus [4-6], and identification of Streptococcus pneumoniae was an independent risk factor for severe disease [7]. Other bacteria, such as Staphylococcus aureus, have been detected in patients with serious complications of influenza [8]. Although the impact of influenza virus–bacterium coinfection has been well described, fewer data exist for other virus-bacterium or virus-virus coinfections. A number of barriers limit our ability to understand important aspects of coinfections. Most of the burden of CAP occurs in outpatient settings, where comprehensive etiologic molecular testing is not performed. Studies of hospitalized children from a single site are generally too small to conduct meaningful analyses of pathogen-pathogen interactions. Common testing algorithms for determining the etiology of CAP also suffer from poor sensitivity and specificity, particularly for bacterial infections, since blood culture is predominantly used to determine the bacterial etiology of pneumonia in children [9]. The use of polymerase chain reaction (PCR) analysis aids in identifying viral causes of pneumonia, but pathogens detected in the upper respiratory tract may not correlate with pathogens obtained directly from the lung. In addition, sequential infections in which one pathogen alters the host’s defenses facilitating a secondary infection are particularly difficult to accurately diagnose, as the preceding pathogen may no longer be detectable when the patient comes to medical attention. The Etiology of Pneumonia in the Community (EPIC) study presented an opportunity to comprehensively study coinfections [1]. This large, multisite, prospective study included a comprehensive assessment of etiology, using multiple state-of-the-art diagnostic tests linked to clinical outcomes. The size of the study and the breadth of demographic, clinical, and diagnostic data available presented an opportunity to overcome many of the barriers cited above to understanding causes of pneumonia, as well as analyzing the impact of coinfection. Coinfections with multiple pathogens were identified in 26% of the children with radiographically defined CAP [1]. Here we explore the interactions of various viral and bacterial organisms in pneumonia and the impact of coinfections on clinical characteristics and outcomes.

METHODS

Study Population and Pathogen Detection

Children (<18 years old) were enrolled in the EPIC study at 3 children’s hospitals in Memphis, Tennessee, Nashville, Tennessee, and Salt Lake City, Utah [1]. Between January 2010 and June of 2012, 2638 children were enrolled, of whom 2358 had final radiographic evidence of pneumonia. Of this cohort, 2219 had specimens tested for both viruses and bacteria and were included in the current analyses (Figure 1). Children with recent hospitalization, tracheostomy, cystic fibrosis, or severe immunosuppressive conditions were excluded [1]. Demographic and clinical data were obtained using previously described methods. Typical bacteria were detected by cultures of blood, pleural fluid, and/or bronchoalveolar lavage specimens and by PCR testing of blood or pleural fluid specimens as described elsewhere [1]. Atypical bacteria, Chlamydophila pneumoniae and Mycoplasma pneumoniae, were detected by PCR analysis of combined nasopharyngeal and oropharyngeal swab specimens. Human adenovirus (hAdV), human coronavirus (hCoV), human metapneumovirus (hMPV), human rhinovirus (hRV), influenza A and B virus, parainfluenza virus (PIV), and respiratory syncytial virus (RSV) were also detected by PCR analysis of combined nasopharyngeal and oropharyngeal swab specimens. Serologic testing for hAdV, hMPV, influenza A and B viruses, PIV, and RSV was also performed on acute and convalescent specimens in 44% of children [1]. The parent study protocol was approved by the University of Tennessee Health Science Center Institutional Review Board, informed consent was obtained from parents or guardians in all cases, and assent was obtained from participants when appropriate.
Figure 1.

Etiology of pneumonia in hospitalized children. In 2219 children hospitalized in the Etiology of Pneumonia in the Community Study, 2506 pathogens were detected. Shown is the percentage of patients with a positive result for each pathogen (on the x-axis) and the total numbers of each pathogen that were detected (numbers beside the bars). Pathogens other than those highlighted here were detected in 78 children, including Staphylococcus aureus (in 22 children), Streptococcus pyogenes (in 16), viridans streptococci (in 13), Chlamydophila pneumoniae (in 12), Haemophilus influenzae (in 9), other gram-negative bacteria (in 9), and other Streptococcus species (in 4). Flu, influenza virus; hADV, human adenovirus; hCoV, human coronavirus; hMPV, human metapneumovirus; hRV, human rhinovirus; Mpn, Mycoplasma pneumoniae; PIV, parainfluenza virus; RSV, respiratory syncytial virus; Spn, Streptococcus pneumoniae.

Etiology of pneumonia in hospitalized children. In 2219 children hospitalized in the Etiology of Pneumonia in the Community Study, 2506 pathogens were detected. Shown is the percentage of patients with a positive result for each pathogen (on the x-axis) and the total numbers of each pathogen that were detected (numbers beside the bars). Pathogens other than those highlighted here were detected in 78 children, including Staphylococcus aureus (in 22 children), Streptococcus pyogenes (in 16), viridans streptococci (in 13), Chlamydophila pneumoniae (in 12), Haemophilus influenzae (in 9), other gram-negative bacteria (in 9), and other Streptococcus species (in 4). Flu, influenza virus; hADV, human adenovirus; hCoV, human coronavirus; hMPV, human metapneumovirus; hRV, human rhinovirus; Mpn, Mycoplasma pneumoniae; PIV, parainfluenza virus; RSV, respiratory syncytial virus; Spn, Streptococcus pneumoniae.

Statistical Analyses

Demographic and clinical characteristics of all cases of CAP were described and stratified in the following groups: viruses, bacteria, or atypical bacteria; viruses-bacteria or viruses–atypical bacteria; and no detection of viruses or bacteria. Children with single-virus infections were similar demographically and clinically to children with virus-virus coinfections and, for clarity, were therefore combined in the viruses group in the tables. The same is true for those with single and multiple typical bacterial pathogens detected, who were combined in the typical bacteria group. Comparisons between types of infection, as defined by these groups, were made using χ2 tests or the Fisher exact test as appropriate for categorical variables and t tests or the Wilcoxon rank sum test as appropriate for continuous variables. We used 2-by-2 tables to estimate whether certain codetections occurred more frequently than would be expected by chance. For each pair of potential coinfections, we tabulated the individual pathogen detections against each other. The frequencies of observed codetected pairs were compared with how often they would be expected to occur by chance. Deviations from expected frequencies were quantified using a χ2 test and then by calculating the odds ratio (OR) and 95% confidence interval (CI) for each pair of pathogens. Age and infection season were not included in the a priori analyses but were assessed post hoc to develop hypotheses that might explain the findings. To assess differences in severity among types of infections, we compared the categorical outcomes of supplemental oxygen use in the first 24 hours, intensive care unit admission, invasive mechanical ventilation use, and hospital length of stay.

RESULTS

Of the 2219 children studied, 1801 (81%) had ≥1 respiratory pathogen detected (Figure 1). Of these, 576 (26%) had a coinfection (Supplementary Table 1), including 417 children with ≥ 2 viruses detected, 99 with ≥ 1 virus and ≥ 1 typical bacterial pathogen, 56 with ≥ 1 virus and ≥ 1 atypical bacterial pathogen, and four with two bacterial pathogens. Children with only viruses detected were younger than children with only typical bacteria detected, and children with only atypical bacteria detected were older than either of these groups (Table 1). Children with only viruses detected were more likely to be black than children with only typical bacterial or atypical bacterial pathogens. The age distribution and race of children with virus-bacterium coinfection most closely resembled those with viral infection alone (Table 1). Children with typical bacterial infection alone, atypical bacterial infection alone, or virus-typical bacterium coinfection were more likely to have no previous underlying medical conditions and less likely to have asthma than children with viral infection alone. No striking differences in body mass index or vaccination history were observed among types of infection. Children with a diagnosis of atypical bacterial infection alone were more likely to have received antibiotics prior to admission than the other groups (Table 1).
Table 1.

Demographic Characteristics of 2219 Participating Children, by Infection Group

CharacteristicViruses (n = 1472)Typical Bacteria (n = 41)Atypical Bacteria (n = 133)Viruses-Typical Bacteria (n = 99)Viruses–Atypical Bacteria (n = 56)No Detection (n = 418)
Age, y, mean ± SD3.2 ± 3.55.7 ± 4.9a8.8 ± 4.3b,c3.1 ± 3.76.2 ± 4.45.9 ± 4.9
Male sex779 (53)27 (66)82 (62)67 (68)d29 (52)240 (57)
Race/ethnicity
 Non-Hispanic white500 (34)24 (59)87 (65)b37 (37)28 (51)196 (47)
 Non-Hispanic black546 (37)7 (17)a21 (16)b30 (30)14 (25)144 (35)
 Hispanic300 (20)7 (17)19 (14)22 (22)11 (20)55 (13)
 Other122 (9)3 (7)6 (5)b10 (10)2 (4)18 (4)
Age group
 <2 y773 (53)11 (27)a10 (8)b,c55 (56)12 (21)118 (28)
 2–4 y397 (27)12 (29)19 (14)b,c25 (25)14 (25)92 (22)
 5–9 y202 (14)12 (29)52 (39)b11 (11)17 (30)114 (27)
 10–17 y100 (7)6 (15)52 (39)c8 (8)13 (23)94 (22)
Comorbidities
 None687 (47)29 (71)a71 (54)c65 (66)d25 (45)194 (46)
 Asthma/reactive airway disease538 (37)8 (20)a37 (28)b19 (19)d21 (38)119 (28)
 Preterm birth (if age <2 y)155 (20)1 (9)5 (50)b10 (18)3 (25)31 (26)
 Neurologic disorder106 (7)1 (2)8 (6)4 (4)1 (2)60 (14)
 Congenital heart disease101 (7)2 (5)13 (10)6 (6)3 (5)34 (8)
 Chromosomal disorder64 (4)2 (5)11 (8)b4 (4)6 (11)39 (9)
BMI statuse
 Underweight130 (20)2 (7)13 (11)5 (12)5 (12)40 (15)
 Normal353 (54)15 (54)70 (58)23 (55)23 (56)136 (52)
 Overweight61 (9)2 (7)18 (15)7 (17)4 (10)28 (11)
 Obese105 (16)9 (32)20 (17)7 (17)9 (22)57 (22)
Up-to-date vaccination statusf
H. influenzae type B1282 (90)35 (82)13 (90)85 (92)53 (95)359 (90)
 Influenza394 (28)8 (22)30 (23)27 (30)13 (24)107 (27)
 Pneumococcal1246 (88)31 (82)90 (68)b79 (86)46 (82)315 (79)
Preadmission medications
 Antibioticg238 (16)11 (26)52 (39)b,c19 (20)13 (25)78 (19)
 Corticosteroid126 (9)1 (2)8 (6)4 (4)5 (9)31 (7)
 Influenza antiviral8 (<1)3 (7)a1 (1)c6 (6)d2 (4)7 (2)

Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the number in the column headings, as the denominator. “Viruses” and “Bacteria” encompass single-pathogen detections and multiple detections.

Abbreviations: H. influenzae, Haemophilus influenzae.

a P < .05, for comparison of viral infections to typical bacterial infections.

b P < .05, for comparison of viral infections to atypical infections.

c P < .05, for comparison of typical bacterial infections to atypical infections.

d P < .05, for comparison of viral infections to combined viral and typical bacterial infections.

eBody mass index (BMI) was calculated as the weight in kilograms divided by the height in meters squared and was determined for children ≥2 years of age.

fDefined as having received age-appropriate dosing for H. influenzae type B and pneumococcal vaccine and current seasonal influenza vaccine.

gWithin 5 days of admission.

Demographic Characteristics of 2219 Participating Children, by Infection Group Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the number in the column headings, as the denominator. “Viruses” and “Bacteria” encompass single-pathogen detections and multiple detections. Abbreviations: H. influenzae, Haemophilus influenzae. a P < .05, for comparison of viral infections to typical bacterial infections. b P < .05, for comparison of viral infections to atypical infections. c P < .05, for comparison of typical bacterial infections to atypical infections. d P < .05, for comparison of viral infections to combined viral and typical bacterial infections. eBody mass index (BMI) was calculated as the weight in kilograms divided by the height in meters squared and was determined for children ≥2 years of age. fDefined as having received age-appropriate dosing for H. influenzae type B and pneumococcal vaccine and current seasonal influenza vaccine. gWithin 5 days of admission. The most common pathogens among codetection pairings are shown in Figure 2. The viruses most commonly identified in CAP, RSV and hRV, were also the viruses most frequently found in combination with other viruses and/or bacteria. Among commonly identified pathogens, influenza virus was not detected with Haemophilus influenzae, and M. pneumoniae was not detected with S. pyogenes or H. influenzae. S. pneumoniae was detected in association with the major viruses detected here in roughly equal proportions (Figure 2). For many other pathogen pairings, however, the distribution of pathogen pairings was different than expected by chance (Figures 2 and 3). For example, hAdV and hRV were detected together more commonly as a pair than expected, based on their relative frequency of detection in the EPIC study; a similar pattern was observed for hCoV and RSV. Although the fifth most common pathogen detected overall, M. pneumoniae was the ninth most common pathogen codetected with other organisms; the relative infrequency of coinfections with M. pneumoniae was noted, particularly when pairings with respiratory viruses were examined (Figure 3). Several virus pairs were also observed less frequently than expected, including hMPV with hRV, PIV, or RSV; PIV with hRV or RSV; and hRV with RSV.
Figure 2.

Frequency of pair-wise associations between pathogens in coinfections. Pair-wise associations, by pathogen, are shown for all coinfections involving the 11 most common pathogens detected in the study; other pathogens are grouped together under “Other Pathogen” (see Supplementary Table 1 for a complete listing of all pathogens detected). A single coinfection with ≥3 pathogens present may be represented multiple times to show all associations.

Figure 3.

Frequency of actual as compared to expected coinfections. The frequencies of commonly observed coinfection pairs are shown relative to how often they would be expected to occur by chance, using the frequencies of detection of the individual pathogens as the baseline. Deviations from expected frequencies were quantified using a χ2 test and then by calculating the odds ratio (OR) and 95% confidence interval (CI) for each pair of pathogens. Flu, influenza virus; hADV, human adenovirus; hCoV, human coronavirus; hMPV, human metapneumovirus; hRV, human rhinovirus; Mpn, Mycoplasma pneumoniae; PIV, parainfluenza virus; RSV, respiratory syncytial virus.

Frequency of pair-wise associations between pathogens in coinfections. Pair-wise associations, by pathogen, are shown for all coinfections involving the 11 most common pathogens detected in the study; other pathogens are grouped together under “Other Pathogen” (see Supplementary Table 1 for a complete listing of all pathogens detected). A single coinfection with ≥3 pathogens present may be represented multiple times to show all associations. Clinical symptoms associated with CAP were generally similar among different infection groupings, and length of illness prior to admission did not differ statistically (Table 2). The total white blood cell count and the percentage of white blood cells that were band forms were significantly higher in the typical bacteria and viruses-typical bacteria groups compared to the viruses group. Chest radiography findings, including consolidation and pleural effusion, were also more common in these 2 groups as compared to the viruses group, whereas infiltrates and a pattern consistent with complicated bronchiolitis were less common (Table 2). Serious outcomes or complications, including parapneumonic effusion, admission to an intensive care unit, and use of mechanical ventilation, were significantly more common in the typical bacteria and viruses-typical bacteria groups as compared to the viruses group; median length of stay was also about twice as long in the typical bacteria and viruses-typical bacteria groups (Table 2). Outcome measures, including intensive care admission, invasive mechanical ventilation, and length of stay, were similar for the typical bacteria group as compared to the viruses-typical bacteria group.
Table 2.

Clinical Characteristics of 2219 Participating Children, by Infection Group

CharacteristicViruses (n = 1472)Typical Bacteria (n = 41)Atypical Bacteria (n = 133)Viruses-Typical Bacteria (n = 99)Viruses–Atypical Bacteria (n = 56)No detection (n = 418)
Time from illness onset to admission, d3 (2–5)4 (2–6)7 (5–9)4 (2–6)5 (3–7)3 (1–6)
 Mean ± SD3.6 ± 2.84.6 ± 3.76.9 ± 3.14.1 ± 2.85.1 ± 3.44.1 ± 3.6
 Median (IQR)3 (2–5)4 (2–6)7 (5–9)4 (2–6)5 (3–7)3 (1–6)
Symptoms
 Cough1417 (96)37 (90)a127 (95)89 (90)b54 (96)373 (89)
 Fever / feverishness1340 (91)39 (95)124 (93)87 (88)52 (93)377 (89)
 Anorexia1105 (75)36 (88)102 (77)80 (81)41 (73)293 (70)
 Dyspnea1061 (72)31 (76)82 (62)71 (72)42 (75)273 (65)
 Fatigue997 (68)33 (81)104 (78)69 (70)41 (73)298 (71)
 Excessive crying984 (67)25 (61)47 (35)59 (60)28 (50)236 (56)
 Wheezing993 (67)17 (41)a57 (43)50 (51)b30 (54)206 (49)
 Nausea809 (55)30 (73)a79 (59)47 (47)b33 (59)212 (51)
 Chest indrawing/retractions693 (47)18 (44)32 (24)45 (45)17 (30)164 (39)
 Chills468 (32)21 (51)a80 (60)39 (39)24 (43)189 (45)
WBC count, cells × 1000/mL, mean ± SD13.1 ± 6.917.6 ± 8.2a10.8 ± 5.217.6 ± 11.5b11.9 ± 6.116.5 ± 8.9
Neutrophils, %, mean ± SD57.8 ± 22.464.4 ± 23.263.9 ± 15.854.6 ± 23.6b60.2 ± 18.965.4 ± 39.4
Bands, %, mean ± SD12.9 ± 13.616.6 ± 15.6a13.1 ± 11.918.6 ± 15.1b15.4 ± 16.312.4 ± 13.4
Chest radiography pattern at admissionc
 Consolidation796 (54)33 (80)a75 (56)71 (72)a35 (63)289 (69)
 Infiltrate818 (56)11 (27)a70 (53)39 (39)a22 (39)161 (39)
 Complicated bronchiolitis388 (26)4 (10)a15 (11)14 (14)a3 (5)51 (12)
 Pleural effusion102 (7)22 (54)a33 (25)43 (43)a15 (27)87 (21)
O2 use in first 24 hours856 (58)20 (49)81 (61)55 (56)30 (54)183 (44)
Antibiotics during admission
 No antibiotic224 (15)0 (0)3 (2)4 (4)4 (7)31 (7)
 One antibiotic338 (23)1 (2)17 (13)6 (6)7 (13)58 (14)
 Multiple antibiotics910 (62)40 (98)113 (85)89 (90)45 (80)329 (79)
Parapneumonic effusion during admission78 (5)27 (66)a28 (21)52 (53)a6 (11)78 (19)
ICU admission293 (20)18 (44)a13 (10)43 (43)a8 (14)88 (21)
Invasive mechanical ventilation, %78 (5)12 (29)a1 (1)26 (26)a2 (4)30 (7)
Length of stay, d
 Mean ± SD4.0 ± 7.57.8 ± 5.3a3.2 ± 3.08.7 ± 7.1d3.5 ± 3.74.1 ± 5.1
 Median (IQR)3 (2–4)7 (4–10)2 (2–4)7 (3–12)2 (2–4.5)3 (1–5)

Data are no. (%) of children, unless otherwise indicated.

Abbreviations: ICU, intensive care unit; IQR, interquartile range; WBC, white blood cell.

a P < .05, for comparison of viral infections to typical bacterial infections.

b P < .05, for comparison of typical bacterial infections to combined viral and typical bacterial infections.

cMore than 1 pattern may be present, so numbers do not add up to 100%.

Extending these analyses beyond the broad groupings in Tables 1 and 2, the differences in outcomes remained significant in comparisons of single viruses or multiple viruses to coinfections between viruses and single typical bacterial pathogens or multiple typical bacterial pathogens (Table 3). Intensive care unit admission, use of invasive mechanical ventilation, and length of stay were all significantly greater when single or multiple viruses were complicated by ≥1 typical bacterial pathogen as compared to infections due to single or multiple viruses alone. Coinfections by viruses and atypical bacteria did not lead to worse outcomes. Two virus-virus coinfections (RSV and hAdV vs hAdV alone; influenza virus and RSV vs influenza virus alone) demonstrated higher rates of supplemental oxygen use in the first 24 hours of hospitalization, compared with single infections alone. Other virus-virus coinfections did not lead to similar findings, and no differences in intensive care unit admission or need for mechanical ventilation were identified (Table 3). Interestingly, children with influenza virus and RSV coinfection had a shorter length of stay than those infected with either influenza virus or RSV alone. Typical bacterial coinfection with RSV was associated with statistically significant increases in the length of hospital admission and the need for invasive mechanical ventilation as compared to infection with RSV alone (Table 3). Intensive care unit admission was also twice as frequent among children with RSV-typical bacterium coinfections, but this difference did not reach statistical significance.
Table 3.

Outcomes Comparing Single-Pathogen Infections to Coinfections

EtiologyO2 Use in the First 24 hICU AdmissionInvasive Mechanical VentilationLength of Stay, d
Infections, % P a Infections, % P a Infections, % P a Mean (IQR) P a
By group
 Any viral pathogen
  Overall (n = 1462)582054.0 (2–4)
   Plus any typical bacterial pathogen (n = 97)55.50142<.00126<.0018.6 (3–11)<.001
   Plus any single typical bacterial pathogen (n = 78)53.33333.00419<.0017.7 (3–10)<.001
 Any single viral pathogen
  Overall (n = 1054)572163.8 (2–4)
   Plus any single typical bacterial pathogen (n = 56)48.20236.00721<.0018.0 (3–9.5)<.001
  Plus any single atypical-bacterial pathogen (n = 40)53.58218.69951.00c3.3 (2.0–4.5).233
 Any single atypical bacterial pathogen
  Overall(n = 133)611013.2 (2–4)
  Plus any viral pathogen (n = 55)53.30015.3234.205c3.5 (2–5).525
  Plus any single viral pathogen (n = 40)53.34418.165c5.134c3.3 (2–4.5).874
  Any single typical bacterial pathogen (n = 31)5235236.8 (3–9)
  Plus any viral pathogen (n = 61)51.94331.67513.2457.1 (3–10).829
  Plus any single viral pathogen (n = 56)48.76136.98321.9018.0 (3–9.5).386
  Plus RSV (n = 17)59.63241.69741.20110.1 (3–11).143
By pathogenb
 hRV
  Overall (n = 348)472263.6 (2–4)
  Plus hAdV (n = 61)61.05420.66810.252c7.4 (1–3).304
  Plus RSV (n = 54)56.25722.9872.334c3.7 (2–4).742
  Plus influenza A/B virus (n = 12)50.8528.475c8.520c3.2 (1.5–3.5).767
 RSV
  Overall (n = 358)662063.9 (2–5)
   Plus any single typical bacterial pathogen (n = 17)59.53641.061c41<.001c10.1 (3–11).006
  Plus hRV (n = 54)56.13122.7222.336c3.8 (2–4).797
  Plus hAdV (n = 43)70.63114.3352.714c3.6 (2–4).650
  Plus hCoV (n = 31)55.20616.5936.6913.7 (2–4).742
  Plus influenza A/B virus (n = 24)79.188211.00c41.00c2.8 (2–3).015
  Plus hMPV (n = 18)72.59222.768c61.00c5.7 (3–5).363
 hAdV
  Overall (n = 50)451683.4 (2–4)
  Plus hRV (n = 61)61.09920.617101.00c7.4 (1–3).284
  Plus RSV (n = 43)70.01614.7832.368c3.6 (2–4).722
 Influenza A/B virus
  Overall (n = 54)562274.9 (2–5)
  Plus RSV (n = 24)79.04621.89141.00c2.8 (2–3).044
  Plus hRV (n = 12)50.7278.433c81.00c3.2 (1.5–3.5).220d
 hMPV
  Overall (n = 165)652454.0 (2–5)
  Plus RSV (n = 18)72.532221.00c61.00c5.7 (3–5).376

Abbreviations: hADV, human adenovirus; hCoV, human coronavirus; hMPV, human metapneumovirus; hRV, human rhinovirus; ICU, intensive care unit; IQR, interquartile range; RSV, respiratory syncytial virus.

aCompared to the overall group or pathogen.

bInfections due to 1 or 2 pathogens only.

cBy the Fisher exact test.

dBy the Wilcoxon rank sum test.

DISCUSSION

Because of the difficulties attributing a specific etiology to a pathogen or to multiple pathogens, the current state of knowledge of the role of coinfections in CAP is limited in several critical areas. Specific potential risk factors for coinfections are not known. Clearly, severe immunosuppression from cancer chemotherapy or untreated human immunodeficiency virus infections predispose to coinfections, but what other factors might be in play? The morbidity and mortality associated with influenza and bacterial superinfections is well described [6, 8, 10–12], but does pairing of other pathogens engender similar modifications to the disease course relative to an infection from a single agent? Are some coinfections milder than single infections because of earlier or stronger engagement of innate immune responses? Are there particular pairs (or other multiples) of pathogens that cooperate or compete, leading to different outcomes? In our large multicenter study, children with viral pneumonia were younger and more likely to have comorbidities such as asthma than other children with pneumonia, but no specific risk factors or distinguishing demographic characteristics were identified for children with virus-bacterium coinfections. When viral and typical bacterial pathogens were codetected, virus-bacterium coinfection clinically more closely resembled typical bacterial pneumonia than viral pneumonia, with these children having a higher frequency of leukocytosis, consolidation, parapneumonic effusion, intensive care unit admission, and need for mechanical ventilation and an increased length of stay, compared with the virus only group. Differences in the outcomes measured in this study did not differ between the typical bacteria group and the viruses-typical bacteria group. RSV infection alone was less severe than RSV-typical bacterium coinfection. These are important observations, as testing algorithms in current use often restrict testing for bacterial pathogens if an initial screen for viral pathogens is positive, to reduce costs and antibiotic use. This might result in some typical bacterial coinfections going undiagnosed, leading to worse outcomes. Virus-virus infections were generally comparable to single-virus infections, with the exception of supplemental oxygen use, which was higher during the first 24 hours of hospitalization in select virus-virus pairings. Children with typical bacterial infections were less likely to have a comorbidity such as asthma as compared to children with viruses alone. Asthma is a well-established risk factor for hospitalization with viruses [13]. The finding that asthma and reactive airway disease were more frequent as comorbidities in the viruses group as compared to the typical bacteria group is therefore not surprising (Table 1). Interestingly, the viruses-typical bacteria group had a low prevalence rate of asthma, which, when coupled with worse outcomes, could lead to the speculation that asthmatics with viral pneumonia were more likely to be admitted for reasons related to their underlying chronic diagnosis, rather than for the severity of their CAP. Alternatively, the immune status of the allergic lung could provide protection from the consequences of these infections. As has been suggested from work in animal models, this could mitigate disease severity [14]. Obesity was identified as a risk factor for severe influenza during the 2009 influenza A(H1N1) pandemic [15]. Although our analyses were limited because of the preponderance of young children in this study, obesity did not appear to be a risk factor for coinfections (Table 1). In support of a body of literature examining influenza-associated coinfections [(6)], virus-typical bacterium coinfections were more severe than virus infections alone, even when multiple viruses were codetected (Tables 2 and 3). In influenza studies, bacterial coinfection is common in severe and fatal cases [7, 11, 16]. In particular, the presence of S. pneumoniae and S. aureus is associated with high morbidity and mortality [7, 8, 17, 18]. Similarly, while very few deaths were observed during this study, serious outcomes occurred more frequently in children with virus-bacterium coinfections as compared to those virus infections, and their length of hospital stay was longer. This finding did not extend to coinfection with atypical bacteria, which may be related to a greater frequency of antibiotic use before admission (Table 1). Intensive care unit admission, use of mechanical ventilation and length of stay were also all increased when RSV was complicated by a typical bacterial pathogen. Unfortunately, despite the extremely large size of the study, the numbers of individual pathogen pairings were too low to examine other individual combinations. Of note, severe outcomes were seen in single-virus infections with all viruses studied but were more common when typical bacteria were involved. Whether some viruses such as hRV could cause severe acute respiratory illness in the absence of a coinfection has been questioned [19]. We observed severe disease at a low frequency with both single hRV infections and coinfections where hRV was detected, but we did not observe a difference between these groups, as others have reported [18]. In general, virus-virus coinfections were not more severe than single-virus infections and did not have worse outcomes (Tables 2 and 3), in agreement with a smaller study [20]. Two combinations of virus-virus pairs yielded increased supplemental oxygen use, compared with infections with a single virus (Table 3). Interestingly, RSV coinfections with influenza virus and hAdV were associated with increased need for supplemental oxygen, suggesting that coinfection with these relatively virulent viruses led to increased severity. Clinical Characteristics of 2219 Participating Children, by Infection Group Data are no. (%) of children, unless otherwise indicated. Abbreviations: ICU, intensive care unit; IQR, interquartile range; WBC, white blood cell. a P < .05, for comparison of viral infections to typical bacterial infections. b P < .05, for comparison of typical bacterial infections to combined viral and typical bacterial infections. cMore than 1 pattern may be present, so numbers do not add up to 100%. Outcomes Comparing Single-Pathogen Infections to Coinfections Abbreviations: hADV, human adenovirus; hCoV, human coronavirus; hMPV, human metapneumovirus; hRV, human rhinovirus; ICU, intensive care unit; IQR, interquartile range; RSV, respiratory syncytial virus. aCompared to the overall group or pathogen. bInfections due to 1 or 2 pathogens only. cBy the Fisher exact test. dBy the Wilcoxon rank sum test. One of the most interesting observations from this study was the distribution of frequencies of specific codetections. A wealth of literature from animal models and epidemiologic studies [6] suggests that viral infections enhance acquisition of bacterial pathogens by hampering immune defenses through a variety of mechanisms. Similarly, studies of the common cold in crowded living conditions suggest similar changes to susceptibility in humans to acquisition of colonization with pathogenic bacteria [21, 22]. However, prior studies have not been large enough to adequately compare the actual frequency of specific pathogen-pathogen pairs in a coinfection to the frequency expected by chance. We report that the observed prevalence of several specific codetections was lower than expected, particularly when examining virus pairings with M. pneumoniae (Figure 3). A smaller study of M. pneumoniae infections noted that codetection with viruses was rare [23]. One hypothesis to explain the relative paucity of M. pneumoniae and virus codetections is that infections with these pathogens exhibit different age and seasonal distributions. Indeed, the mean age of children presenting with M. pneumoniae in the study was 98 months, while the mean age for children hospitalized with respiratory viruses ranged from 25 months (for hAdV and RSV) to 63 months (for influenza virus) (Supplementary Figure 1). Stratification of the analyses by age (<5 years and ≥5 years) demonstrated a similar magnitude of effect as compared to the overall study population, although the CIs were wider and crossed 0 in some cases, suggesting decreased power to examine the interactions (Supplementary Figures 2 and 3). In addition, M. pneumoniae was not detected with H. influenzae or S. pyogenes, common bacterial pathogens of the upper respiratory tract. This may be due to the low numbers of bacterial infections in the study, or it may be related to competition within the upper respiratory tract between bacteria, as has been observed in bacterial coinfection models [24]. Frequency of actual as compared to expected coinfections. The frequencies of commonly observed coinfection pairs are shown relative to how often they would be expected to occur by chance, using the frequencies of detection of the individual pathogens as the baseline. Deviations from expected frequencies were quantified using a χ2 test and then by calculating the odds ratio (OR) and 95% confidence interval (CI) for each pair of pathogens. Flu, influenza virus; hADV, human adenovirus; hCoV, human coronavirus; hMPV, human metapneumovirus; hRV, human rhinovirus; Mpn, Mycoplasma pneumoniae; PIV, parainfluenza virus; RSV, respiratory syncytial virus. Several virus-virus pairings were also uncommonly observed. Interestingly, an additional virus-virus interaction, hAdV and RSV, was also significantly less common than expected when analyzing only children aged <5 years (Supplementary Figure 2). The simplest explanation would be differences in seasonality that limited temporal circulation together and thus minimized the chance of a codetection (Supplementary Figure 4). Because we were studying children hospitalized with pneumonia and not a broader population, further analyses regarding the impact of seasonality were not possible. Another hypothesis is that induction of interferon by a first virus protects against the second virus. At least 2 studies have suggested that circulation of rhinoviruses delays or reduces the circulation of other viruses, as was seen in this study with hRV pairings with RSV, PIV, and hMPV [25, 26]. This and other hypotheses should be studied in model systems. Unfortunately, the prevalence of specific bacterial infections was too low for a similar analysis to be performed for specific virus and bacterium pairings. From existing observational studies and animal models (eg, mouse and ferret models of influenza virus and S. pneumoniae coinfection [27, 28]) one would have expected an increased frequency of specific pathogen pairings relative to chance. Why this was seen for hAdV and RSV and for hCoV and RSV but not other pairings is unclear; further study is indicated to replicate and potentially explain these findings. This study has several limitations and challenges. Detection of bacteria in patients with CAP is difficult and may have caused misclassification of some virus-bacterium coinfections into the viruses-only group. The assays to determine etiology and define classes of infections did not include all possible viral and bacterial respiratory pathogens, which may also have caused misclassification, and only 44% of children had acute and convalescent serum specimens available for serologic testing. Some results may be confounded by factors such as age, comorbidities, or strong seasonal circulation of certain viruses; the analyses were unadjusted for these potential confounders. We also could not adjust for the likelihood of hospitalization with each pathogen, which will bias the determination of the frequency of codetection in the hospital downward if patients infected with the pathogen in the community are more likely to be admitted than patients not infected with the pathogen. Finally, the contribution of any specific pathogen to the severity of infection cannot be determined with certainty; on average, 3% of asymptomatic controls (and up to 17% with hRV) in the EPIC study had a virus detected [1]. Nevertheless, this study was very large and comprehensive in its assessment of the etiology of coinfections and the demographic characteristics and outcomes of these children hospitalized for CAP. This allowed pathogen-specific analyses that could not have been attempted with smaller studies. The findings of differences in clinical characteristics and severity of outcomes with virus-typical bacterium coinfections as compared to viruses alone and the few observed differences in comparisons of single-virus infections to multiple-virus infections or of single-typical bacterium infections to virus-typical bacterium infections have important implications for the diagnosis and management of CAP in children. In particular, better detection methods are needed for a broad array of pathogens, and studies to update clinical testing patterns should take into account these findings.

Supplementary Data

Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. Click here for additional data file. Click here for additional data file.
  28 in total

1.  Spread of Streptococcus pneumoniae in families. II. Relation of transfer of S. pneumoniae to incidence of colds and serum antibody.

Authors:  J M Gwaltney; M A Sande; R Austrian; J O Hendley
Journal:  J Infect Dis       Date:  1975-07       Impact factor: 5.226

Review 2.  The co-pathogenesis of influenza viruses with bacteria in the lung.

Authors:  Jonathan A McCullers
Journal:  Nat Rev Microbiol       Date:  2014-03-03       Impact factor: 60.633

3.  Effects of bacterial and viral co-infections of mycoplasma pneumoniae pneumonia in children: analysis report from Beijing Children's Hospital between 2010 and 2014.

Authors:  Qing Song; Bao-Ping Xu; Kun-Ling Shen
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation.

Authors:  Elisa Estenssoro; Fernando G Ríos; Carlos Apezteguía; Rosa Reina; Jorge Neira; Daniel H Ceraso; Cristina Orlandi; Ricardo Valentini; Norberto Tiribelli; Matías Brizuela; Carina Balasini; Sebastián Mare; Gustavo Domeniconi; Santiago Ilutovich; Alejandro Gómez; Javiera Giuliani; Cecilia Barrios; Pascual Valdez
Journal:  Am J Respir Crit Care Med       Date:  2010-03-04       Impact factor: 21.405

5.  Community-acquired pneumonia requiring hospitalization among U.S. children.

Authors:  Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

6.  Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections.

Authors:  James R Gill; Zong-Mei Sheng; Susan F Ely; Donald G Guinee; Mary B Beasley; James Suh; Charuhas Deshpande; Daniel J Mollura; David M Morens; Mike Bray; William D Travis; Jeffery K Taubenberger
Journal:  Arch Pathol Lab Med       Date:  2010-02       Impact factor: 5.534

7.  Rhinoviruses delayed the circulation of the pandemic influenza A (H1N1) 2009 virus in France.

Authors:  J S Casalegno; M Ottmann; M Bouscambert Duchamp; V Escuret; G Billaud; E Frobert; F Morfin; B Lina
Journal:  Clin Microbiol Infect       Date:  2010-01-28       Impact factor: 8.067

8.  Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection.

Authors:  Lyn Finelli; Anthony Fiore; Rosaline Dhara; Lynnette Brammer; David K Shay; Laurie Kamimoto; Alicia Fry; Jeffrey Hageman; Rachel Gorwitz; Joseph Bresee; Timothy Uyeki
Journal:  Pediatrics       Date:  2008-10       Impact factor: 7.124

9.  Nod1 signaling overcomes resistance of S. pneumoniae to opsonophagocytic killing.

Authors:  Elena S Lysenko; Thomas B Clarke; Mikhail Shchepetov; Adam J Ratner; David I Roper; Christopher G Dowson; Jeffrey N Weiser
Journal:  PLoS Pathog       Date:  2007-08-24       Impact factor: 6.823

10.  The immune profile associated with acute allergic asthma accelerates clearance of influenza virus.

Authors:  Amali E Samarasinghe; Stacie N Woolard; Kelli L Boyd; Scott A Hoselton; Jane M Schuh; Jonathan A McCullers
Journal:  Immunol Cell Biol       Date:  2014-01-28       Impact factor: 5.126

View more
  25 in total

1.  Attenuation of Influenza A Virus Disease Severity by Viral Coinfection in a Mouse Model.

Authors:  Andres J Gonzalez; Emmanuel C Ijezie; Onesmo B Balemba; Tanya A Miura
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

2.  Assessment of nasopharyngeal Streptococcus pneumoniae colonization does not permit discrimination between Canadian children with viral and bacterial respiratory infection: a matched-cohort cross-sectional study.

Authors:  Jeffrey M Pernica; Kristin Inch; Haifa Alfaraidi; Ania Van Meer; Redjana Carciumaru; Kathy Luinstra; Marek Smieja
Journal:  BMC Infect Dis       Date:  2021-05-31       Impact factor: 3.090

Review 3.  Host-pathogen kinetics during influenza infection and coinfection: insights from predictive modeling.

Authors:  Amber M Smith
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

4.  In situ Immune Signatures and Microbial Load at the Nasopharyngeal Interface in Children With Acute Respiratory Infection.

Authors:  Kiyoshi F Fukutani; Cristiana M Nascimento-Carvalho; Maiara L Bouzas; Juliana R Oliveira; Aldina Barral; Tim Dierckx; Ricardo Khouri; Helder I Nakaya; Bruno B Andrade; Johan Van Weyenbergh; Camila I de Oliveira
Journal:  Front Microbiol       Date:  2018-11-09       Impact factor: 5.640

Review 5.  Multiplex Platforms for the Identification of Respiratory Pathogens: Are They Useful in Pediatric Clinical Practice?

Authors:  Susanna Esposito; Antonella Mencacci; Elio Cenci; Barbara Camilloni; Ettore Silvestri; Nicola Principi
Journal:  Front Cell Infect Microbiol       Date:  2019-06-04       Impact factor: 5.293

6.  Validation of a host response test to distinguish bacterial and viral respiratory infection.

Authors:  Emily C Lydon; Ricardo Henao; Thomas W Burke; Mert Aydin; Bradly P Nicholson; Seth W Glickman; Vance G Fowler; Eugenia B Quackenbush; Charles B Cairns; Stephen F Kingsmore; Anja K Jaehne; Emanuel P Rivers; Raymond J Langley; Elizabeth Petzold; Emily R Ko; Micah T McClain; Geoffrey S Ginsburg; Christopher W Woods; Ephraim L Tsalik
Journal:  EBioMedicine       Date:  2019-10-17       Impact factor: 8.143

7.  Combined influence of practice guidelines and prospective audit and feedback stewardship on antimicrobial treatment of community-acquired pneumonia and empyema in children: 2012 to 2016.

Authors:  Nicole M A Le Saux; Jennifer Bowes; Isabelle Viel-Thériault; Nisha Thampi; Julie Blackburn; Melanie Buba; Mary-Ann Harrison; Nick Barrowman
Journal:  Paediatr Child Health       Date:  2020-06-30       Impact factor: 2.253

Review 8.  Co-infections as Modulators of Disease Outcome: Minor Players or Major Players?

Authors:  Priti Devi; Azka Khan; Partha Chattopadhyay; Priyanka Mehta; Shweta Sahni; Sachin Sharma; Rajesh Pandey
Journal:  Front Microbiol       Date:  2021-07-06       Impact factor: 5.640

9.  Influenza and Bacterial Coinfection in Adults With Community-Acquired Pneumonia Admitted to Conventional Wards: Risk Factors, Clinical Features, and Outcomes.

Authors:  Gabriela Abelenda-Alonso; Alexander Rombauts; Carlota Gudiol; Yolanda Meije; Lucía Ortega; Mercedes Clemente; Carmen Ardanuy; Jordi Niubó; Jordi Carratalà
Journal:  Open Forum Infect Dis       Date:  2020-02-27       Impact factor: 3.835

10.  Rhinovirus Reduces the Severity of Subsequent Respiratory Viral Infections by Interferon-Dependent and -Independent Mechanisms.

Authors:  James T Van Leuven; Andres J Gonzalez; Emmanuel C Ijezie; Alexander Q Wixom; John L Clary; Maricris N Naranjo; Benjamin J Ridenhour; Craig R Miller; Tanya A Miura
Journal:  mSphere       Date:  2021-06-23       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.